Blood Thinners Called Factor Xa Inhibitors Lower Heart Risk in Elderly with Atrial Fibrillation
05-14-2025"To the best of our knowledge, this is the first study to address the effects of Xa-Is on composite cardiovascular events, congestive heart failure, arteriosclerotic disease, and cardiovascular death among very old patients with NVAF over a long-term follow-up period.”
Click here to listen to this press release
BUFFALO, NY — May 14, 2025 — A new research paper was published in Aging (Aging-US) Volume 17, Issue 4, on April 10, 2025, titled “Impact of Factor Xa inhibitors on cardiovascular events in older patients with nonvalvular atrial fibrillation.”
In this study, first author Masahiko Takahashi and corresponding author Keisuke Okawa led a research team from Kagawa Prefectural Central Hospital and Hyogo Medical University that investigated whether Factor Xa inhibitors (Xa-Is)—a type of blood thinner—can reduce the risk of heart-related complications in patients over 80 with nonvalvular atrial fibrillation (NVAF). The study found that patients using Xa-Is experienced significantly fewer cardiovascular problems than those on other anticoagulants. This finding is especially relevant, as older adults face a high risk of both stroke and heart disease.
Atrial fibrillation is a common heart rhythm disorder, particularly in the elderly, that increases the risk of blood clots, heart failure, and stroke. Anticoagulants are often prescribed to prevent clots, but not all types have the same effects on heart health. This study focused on comparing Xa-Is—specifically rivaroxaban, apixaban, and edoxaban—with commonly used drugs such as warfarin and dabigatran.
Researchers followed more than 1,000 patients aged 80 and above for up to five years to assess the long-term impact of these medications on cardiovascular outcomes. Patients who used Xa-Is had significantly lower rates of heart failure, artery disease, and cardiovascular death. The risk of cardiovascular problems in the Xa-I group was less than half that of those on non-Xa-I medications. These benefits remained even after adjusting for factors like age, existing heart conditions, and kidney function. Additionally, stroke and all-cause death rates were notably lower in the Xa-I group.
“Xa-Is may be useful for not only anticoagulation but also the prevention of cardiovascular events in very old patients with NVAF.”
What makes Xa-Is different, according to the researchers, is their ability to inhibit a specific biological pathway—known as Factor Xa–PAR2—that contributes to inflammation, fibrosis, and damage in blood vessels and heart tissue. This effect extends beyond their traditional role in preventing blood clots. Although the study was conducted at a single medical center in Japan, its rigorous design and long follow-up period enhance the reliability of the findings for real-world clinical decision-making.
While further studies, especially across multiple centers, are needed to confirm the full range of benefits, this study strongly suggests that Xa-Is may offer broader cardiovascular protection for very old patients. The findings could influence how clinicians choose blood thinners for elderly individuals with atrial fibrillation, potentially improving both survival and quality of life in this growing population.
Read the full paper: DOI: https://doi.org/10.18632/aging.206238
Corresponding author: Keisuke Okawa - k-ookawa@chp-kagawa.jp
Keywords: aging, Factor Xa inhibitor, atrial fibrillation, older patient, cardiovascular events
Click here to sign up for free Altmetric alerts about this article.
______________
Aging (Aging-US)
To learn more about Aging (Aging-US), please visit our website at www.Aging-US.com and connect with us on social media at:
- X
- YouTube
- Bluesky
- Spotify, or available wherever you listen to podcasts
For media inquiries, please contact media@impactjournals.com.